BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Made for today, tomorrow and for what’s needed next.
Ethics and Compliance
At BD, we are committed to a strong ethics and compliance culture. We do not tolerate actions or behaviors that are inconsistent with our values or violate the BD Code of Conduct or applicable laws and regulations. All BD associates are responsible for reinforcing our ethics and compliance culture and sustaining our reputation as a company dedicated to quality and integrity. We encourage and expect everyone at BD to speak up by asking questions, raising concerns, seeking guidance, and reporting actual or suspected violations of laws, our Code of Conduct, our policies, or our high ethical standards. This requirement extends to all associates, vendors, and other third parties working on our behalf.
2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second).
2022 BD celebrates their 125th anniversary by ringing the closing bell at the New York Stock Exchange.
2021 BD launched the first atherectomy and thrombectomy device in the U.S. indicated to treat in-stent restenosis.
2021 BD launched the first at-home system in the U.S. indicated for malignant and non-malignant ascites drainage.
2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution.
2021 BD launched the first assay for HPV screening from at-home, self-collected vaginal samples.
2021 BD launched the first smartphone-interpreted rapid at-home COVID-19 test.
2020 BD launched the first Human Papillomavirus (HPV) test with extended genotyping to detect more types of HPV, the dominant cause of cervical cancer.
2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process.
2020 BD launched the BD Veritor™ Plus System for rapid detection of COVID-19
2019 BD launched the first CHG antiseptic skin preparation product with sterile solution in the U.S.
2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease.
2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.
2017 BD acquired C. R. Bard, a medical device company founded in 1907 in Covington, Georgia.
2015 BD became the first to integrate IV pumps with electronic health records.
2015 BD acquired CareFusion, a San Diego, California-based medical technology company specializing in two areas: reducing medication errors and prevention of health care-associated infections.
2014 BD AutoShield Duo™ Safety Pen Needle with Duel Automatic Protective Shields is launched at retail.
2014 BD launched the first FDA-approved drug coated balloon for peripheral artery disease.
2010 BD Ultra-Fine™ Nano™ Pen Needle is launched.
2009 BD Vacutainer® RST™ Tube is approved by the FDA.
2007 BD participates in PEPFAR, the U.S. government's global effort to combat HIV and the largest global health program devoted to a single disease.
2007 BD AutoShield™ needle is launched.
2004 BD introduced the first power-injectable PICC (Peripherally Inserted Central Catheter).
2003 BD launched the BD FACSAria™ Cell Sorter.
2002 BD opened new distribution center in Redlands, California.
2000 BD launched the BD Nexiva™ Closed IV Catheter System.
1999 BD announced a 5-year partnership with UNICEF and the U.S. Fund for UNICEF to help eliminate maternal and neonatal tetanus worldwide.
1999 The world’s shortest, thinnest insulin pen needle is introduced.
1997 BD celebrated their 100th anniversary with a refresh to their brand identity.
1995 A joint venture was established in China to produce medical products for China.
1995 BD formed a subsidiary in India to manufacture insulin syringes and to market other medical and diagnostic products to the region.
1993 BD launched the first simplified CD4 instrument for HIV.
1992BD introduced the BD Vacutainer® Safety-Lok™ Blood Collection Set.
1991BD launched the first auto-disable immunization device.
1991Pen needle is introduced.
1991BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa.
1990Sales surpass $2,000,000,000 for the first time.
1989 BD launched the Pyxis MedStation™ 1000 System: the world’s first automated medication dispensing cabinet.
1988 BD launched the first safety engineered syringe.
1987 BD opened a new manufacturing facility in Singapore.
1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan.
1986BD HQ is moved from Rutherford, NJ to Franklin Lakes, NJ.
1986 BD builds a leadership position in peripheral vascular access devices.
1985 BD became the first to harness the highly specific bind properties of monoclonal antibodies.
1981 BD launched the Bactec™ 460TB instrument – the first automated system for TB testing.
1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.
1981 BD sales surpassed $1,000,000,000 for the first time.
1980BD launched the first automated system for mycobacteria testing.
1975BD opened its European HQ in Meylan, France.
1973BDopened anew research center in Research Triangle Park, North Carolina.
1972BD launched the first florescence-activated cell sorter.
1971BD launched the Baby Bird® ventilator, the first infant ventilator.
1971BD launched the first automated blood culture system.
1968 BD introduced the first automated blood culture system for TB.
1963 BD invited to join the New York Stock Exchange.
1962 BD launched the first mass production of syringes and needles.
1962 BD became a public company.
1961BD introduced the Plastipak™ Syringe.
1956 BD enters the Brazilian syringe market and quickly becomes the largest provider in the country with two modern plants and HQ in Sao Paulo.
1955 BD enters the microbiology field leading to two fundamental innovations: The conversion of sterilized disposables and the emergence of diagnostic medicine.
1955 BD begins using AMI of France to manufacture steel tubes for hypodermic needles. Three years later, BD would acquire AMI and establish BD France S.A.
1954 Production of the first disposable syringes to be used in the Salk Polio vaccine trial takes place.
1952 BD launched the first sterile disposable medical device.
1952 BD acquired MAPAD, S.A. de C.V. based in Mexico City, to produce syringes, needles and clinical thermometers for the Mexican market.
1951 The formation of BD Canada, Ltd. marks the beginning of BD international expansion.
1949 Wesley J. “Jack” Howe joins BD and becomes integral to developing sterility control procedures and refining the process for manufacturing disposable syringes and needles.
1949 BD opens its first manufacturing site outside of New Jersey in Columbus, Nebraska.
1949BD launchedthe first Vacutainer® blood collection tube.
1948 BD founders turn over the company to their sons.
1947 BD hired Joseph Kleiner, who brings his multi-fit syringe and his idea for the evacuated tube. (Patented in 1949)
1942 BD launched the first penicillin injection kit.
1940BD launched the first sterilization technology for devices.
1925 BD acquired the Yale™ Luer-Lok™ — the first simple, secure method for attaching and removing a needle from a syringe.
1924 BD launched the first insulin injection device.
1921 Andrew W. “Doc” Fleischer, developer of the mercurial sphygmomanometer, merged his company with BD. Doc Fleischer would go on to develop the modern stethoscope.
1913BD merged with Oscar O.R. Schwidetzky’s surgical import company, bringing his Asepto™ bulb syringe along with helping to develop the American-made ACE® bandage.
1906 BD opened the first syringe and needle factory in the United States.
1898 BD acquired its first patent for an all-glass syringe.
1897BD is founded.
Honors and Recognition
Environment,
social and governance
2021 Bloomberg Gender Equality Index
Environment,
Social and Governance
Fortune Change the World 2020
Technology and Innovation
2021 Clarivate Top 100 Global Innovator
Environment,
Social and Governance
2021 DiversityInc Noteworthy Company
Environment,
Social and Governance
2021 Disability Equality Index
Environment,
Social and Governance
2021 Best Place to Work for LGBTQ Equality
Environment,
social and governance
2021 Bloomberg Gender Equality Index
Environment,
Social and Governance
Fortune Change the World 2020
Technology and Innovation
2021 Clarivate Top 100 Global Innovator
Environment,
Social and Governance
2021 DiversityInc Noteworthy Company
Environment,
Social and Governance
2021 Disability Equality Index
Environment,
Social and Governance
2021 Best Place to Work for LGBTQ Equality
Environment,
social and governance
2021 Bloomberg Gender Equality Index
Environment,
Social and Governance
Fortune Change the World 2020
BD Interventional
The BD Interventional segment focuses on developing innovative surgical, endovascular, urological and critical care interventions that not only meet clinical needs but also deliver value to health systems and improve patients’ lives. Our customers include hospitals and clinics; physicians; ambulatory surgery centers; nurses; and consumers.
BUSINESS UNITS
Peripheral Intervention
Surgery
Urology and Critical Care
BD Medical
The BD Medical segment focuses on providing innovative solutions to reduce the spread of infection, advance drug delivery, improve surgical procedures, deliver advanced hemodynamic monitoring capabilities, and provide effective and safe medication management. Our customers include hospitals and clinics; physicians; governmental and public health agencies; healthcare workers; retail pharmacies; and pharmaceutical and biotech companies.
BUSINESS UNITS
Advanced Patient Monitoring
Medication Delivery Solutions
Medication Management Solutions
Pharmaceutical Systems
BD Life Sciences
The BD Life Sciences segment delivers innovative solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Offerings include preanalytical solutions for sample management; immunology research solutions, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics solutions; and differentiated reagents and assays.
BUSINESS UNITS
Biosciences
Diagnostic Solutions
Specimen Management
Executive Leadership
Richard Byrd
Executive Vice President and President, Interventional Segment
